In combination with a risk factor-informed bGWAS, this analysis identified 2 known susceptibility loci for NAFLD (TM6SF2 and PNPLA3) and 5 potentially new candidate genetic regions for a clinical diagnosis NAFLD based on EHRs (GCKR, TRIB1, LPL, FTO, APOE). This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.